Nutriband (NASDAQ:NTRB) Trading 2.3% Higher – What’s Next?

Nutriband Inc. (NASDAQ:NTRB) shares traded up 2.3% during mid-day trading on Wednesday . The company traded as high as $3.59 and last traded at $3.53. 7,163 shares were traded during trading, a decline of 24% from the average session volume of 9,477 shares. The stock had previously closed at $3.45.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nutriband in a report on Friday, May 8th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Nutriband presently has an average rating of “Reduce”.

Nutriband Stock Up 4.3%

The company has a market capitalization of $44.26 million, a P/E ratio of -1.40 and a beta of 1.96. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.21 and a current ratio of 6.36. The stock has a 50 day moving average price of $3.83 and a 200 day moving average price of $4.39.

Institutional Investors Weigh In On Nutriband

A hedge fund recently raised its stake in Nutriband stock. Vanguard Group Inc. boosted its position in Nutriband Inc. (NASDAQ:NTRB) by 1.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 202,738 shares of the company’s stock after acquiring an additional 3,111 shares during the period. Vanguard Group Inc. owned 1.68% of Nutriband worth $1,429,000 as of its most recent SEC filing. 19.70% of the stock is currently owned by institutional investors.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.